Particle-based vaccines for transcutaneous vaccination

被引:77
作者
Combadiere, Behazine [1 ]
Mahe, Brice [1 ]
机构
[1] Univ Paris 06, INSERM, U543, Inst Natl Sante & Rech Med, F-75634 Paris, France
关键词
nanoparticles; skin; immune responses; vaccination;
D O I
10.1016/j.cimid.2007.07.015
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immunization concepts evolve with increasing knowledge of how the immune system works and the development of new vaccination methods. Traditional vaccines arc made of live, attenuated, killed or fragmented pathogens. New vaccine strategies can take advantage of particulate compounds-microspheres or nanoparticles-to target antigen-presenting cells better, which must subsequently reach the secondary lymphoid organs, which are the sites of the immune response. The use of the skin as a target organ for vaccine delivery sterns from the fact that immature dendritic cells (DCs), which are professional antigen-presenting cells can be found at high density in the epidermis and dermis of human or animal skin. This has led to design various methods of dermal or transcutaneous vaccination. The quality and duration of the humoral and cellular responses to vaccination depend on the appropriate targeting of antigen-presenting cells, of the vaccine close, route of administration and use of adjuvant. In this review, we will focus on the use of micro- and nano-particles to target the skin antigen-presenting cells and will discuss recent advances in the field of transcutaneous vaccination in animal models and humans. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:293 / 315
页数:23
相关论文
共 171 条
[1]   Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes [J].
Abadie, V ;
Badell, E ;
Douillard, P ;
Ensergueix, D ;
Leenen, PJM ;
Tanguy, M ;
Fiette, L ;
Saeland, S ;
Gicquel, B ;
Winter, N .
BLOOD, 2005, 106 (05) :1843-1850
[2]   Targeting dendritic cells with antigen-containing liposomes: antitumour immunity [J].
Altin, JG ;
van Broekhoven, CL ;
Parish, CR .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (11) :1735-1747
[3]  
ALVING CR, 1991, CRIT REV IMMUNOL, V10, P441
[4]   Immunogenicity and protectivity of a new liposomal hepatitis A vaccine [J].
Ambrosch, F ;
Wiedermann, G ;
Jonas, S ;
Althaus, B ;
Finkel, B ;
Gluck, R ;
Herzog, C .
VACCINE, 1997, 15 (11) :1209-1213
[5]   Pox viral vaccine approaches [J].
Arlen, PM ;
Kaufman, HL ;
DiPaola, RS .
SEMINARS IN ONCOLOGY, 2005, 32 (06) :549-555
[6]   Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models [J].
Ataman-Onal, Yasemin ;
Munier, Severine ;
Ganee, Arnaud ;
Terrat, Celine ;
Durand, Pierre-Yves ;
Battail, Nicole ;
Martinon, Frederic ;
Le Grand, Roger ;
Charles, Marie-Helene ;
Delair, Thierry ;
Verrier, Bernard .
JOURNAL OF CONTROLLED RELEASE, 2006, 112 (02) :175-185
[7]   Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro [J].
Audran, R ;
Peter, K ;
Dannull, J ;
Men, Y ;
Scandella, E ;
Groettrup, M ;
Gander, B ;
Corradin, G .
VACCINE, 2003, 21 (11-12) :1250-1255
[8]   Effects of IL-12 on immune responses induced by transcutaneous immunization with antigens formulated in a novel lipid-based biphasic delivery system [J].
Baca-Estrada, ME ;
Foldvari, M ;
Ewen, C ;
Badea, I ;
Babiuk, LA .
VACCINE, 2000, 18 (17) :1847-1854
[9]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[10]   Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF [J].
Barouch, DH ;
Santra, S ;
Tenner-Racz, K ;
Racz, P ;
Kuroda, MJ ;
Schmitz, JE ;
Jackson, SS ;
Lifton, MA ;
Freed, DC ;
Perry, HC ;
Davies, ME ;
Shiver, JW ;
Letvin, NL .
JOURNAL OF IMMUNOLOGY, 2002, 168 (02) :562-568